TScan Therapeutics, Inc.
TCRX
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Profil
TScan Therapeutics, Inc., preklinická biofarmaceutická společnost, vyvíjí T-buněčné receptory navržené T-buněčné terapie pro léčbu pacientů s nádorovým onemocněním. Vyvíjí TSC- 100 a TSC- 101 pro léčbu pacientů s hematologickými malignitami k eliminaci reziduální leukémie a prevenci relapsu po transplantaci hematopoetických kmenových buněk; a TSC- 200, TSC- 201, TSC- 202, TSC- 203 a TSC- 204 pro léčbu solidních tumorů. Společnost také vyvíjí vakcíny proti infekčním onemocněním, jako je SARS-CoV-2. Společnost Novartis Institutes for BioMedical Research, Inc., spolupracuje a uzavírá licenční smlouvu s cílem identifikovat nové antigeny rakoviny z T buněk pacientů s určitým specifickým typem rakoviny. Společnost TScan Therapeutics, Inc. byla založena v roce 2018 a sídlí ve Walthamu v Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
200
Založení
2021-07-16
Podobné společnosti
$ 2.00
+ $ 0.12
$ 2.83
+ $ 0.18
$ 1.32
+ $ 0.01
$ 0.39
- $ 0.02
$ 2.36
+ $ 0.02
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 10.3 | 10.3 | 2.8 | 21.0 | 13.5 | 10.1 | 1.1 | 0.0 | |
| Cost of Revenues | 1.5 | 2.9 | 0.0 | 88.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 8.8 | 7.5 | 2.8 | -67.1 | 13.5 | 10.1 | 1.1 | 0.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 2.6 | 2.5 | 3.1 | 2.2 | 0.7 | 1.0 | 0.5 | 0.6 | 7.2 | 3.9 | |
| Cost of Revenues | 0.7 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.3 | |
| Gross Profit | 1.8 | 1.7 | 3.1 | 2.2 | 0.7 | 1.0 | 0.5 | 0.6 | 5.9 | 2.6 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 88.2 | 59.8 | 45.0 | 20.6 | 9.4 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 26.4 | 20.4 | 13.8 | 6.7 | 4.8 | |
| Depreciation & Amortization | 2.9 | 2.9 | 4.1 | 5.4 | 1.6 | 3.3 | 1.2 | 0.5 | |
| Total Operating Expenses | 144.6 | 143.3 | 137.6 | 114.5 | 80.2 | 58.8 | 27.3 | 14.2 | |
| Operating Income | -135.8 | -135.8 | -134.8 | -93.5 | -66.6 | -48.6 | -26.2 | -14.2 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 22.4 | 22.7 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.9 | 5.9 | ||
| Depreciation & Amortization | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 | 1.0 | 1.1 | 1.3 | 1.3 | 1.3 | ||
| Total Operating Expenses | 25.7 | 38.8 | 41.7 | 38.4 | 37.4 | 33.7 | 34.7 | 31.9 | 27.3 | 28.6 | ||
| Operating Income | -23.9 | -37.1 | -38.7 | -36.3 | -36.7 | -32.6 | -34.1 | -31.4 | -21.4 | -24.7 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 6.8 | 8.8 | 12.1 | 8.0 | 1.6 | 0.0 | 0.1 | 0.6 | |
| Interest Expense | 2.8 | 2.8 | 3.7 | 3.8 | 1.2 | 0.0 | 0.0 | 0.0 | |
| Other Expense | 6.0 | 6.0 | 7.3 | 4.2 | 0.4 | 0.0 | 0.1 | 0.6 | |
| IBT | -129.8 | -129.8 | -127.5 | -89.2 | -66.2 | -48.6 | -26.1 | -13.7 | |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.0 | -0.1 | -0.6 | |
| Net Income | -129.8 | -129.8 | -127.5 | -89.2 | -65.8 | -48.6 | -26.0 | -13.1 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 1.6 | 0.0 | 2.4 | 2.8 | 2.8 | 3.7 | 3.4 | 2.2 | 2.6 | 2.7 | ||
| Interest Expense | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 1.0 | 1.0 | 1.0 | 0.9 | 1.0 | ||
| Other Expense | 0.9 | 1.3 | 1.7 | 2.1 | 0.9 | 2.7 | 2.5 | 1.2 | 1.7 | 1.8 | ||
| IBT | -23.0 | -35.7 | -37.0 | -34.1 | -35.8 | -29.9 | -31.7 | -30.1 | -19.6 | -23.0 | ||
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | -1.3 | ||
| Net Income | -23.0 | -35.7 | -37.0 | -34.1 | -35.8 | -29.9 | -31.7 | -30.1 | -19.6 | -23.0 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.36 | $-2.74 | $-4.17 | $-1.09 | $-0.55 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.36 | $-2.74 | $-4.17 | $-1.09 | $-0.55 | |
| Shares Outstanding | 129.9 | 129.9 | 112.0 | 65.6 | 24.0 | 11.7 | 23.9 | 23.9 | |
| Diluted Shares Outstanding | 129.9 | 129.9 | 112.0 | 65.6 | 24.0 | 11.7 | 23.9 | 23.9 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.21 | $-0.24 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.21 | $-0.24 | ||
| Shares Outstanding | 129.9 | 129.8 | 129.7 | 129.7 | 120.8 | 118.7 | 113.4 | 94.9 | 94.8 | 94.8 | ||
| Diluted Shares Outstanding | 129.9 | 129.8 | 129.7 | 129.7 | 120.8 | 118.7 | 113.4 | 94.9 | 94.8 | 94.8 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 242.2 | 178.7 | 133.4 | 120.0 | 161.4 | 34.8 | 41.8 | |
| Short Term Investments | 55.5 | 111.4 | 58.7 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 297.7 | 290.1 | 192.0 | 120.0 | 161.4 | 34.8 | 41.8 | |
| Accounts Receivable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 1.9 | 2.6 | 2.2 | 4.1 | 4.2 | 0.0 | 0.0 | |
| Total Current Assets | 299.5 | 292.7 | 194.2 | 120.0 | 165.7 | 36.4 | 42.4 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 169.5 | 169.4 | 154.1 | 178.7 | 133.1 | 242.2 | 140.5 | 133.4 | 155.2 | 208.8 | |
| Short Term Investments | 14.9 | 48.7 | 97.6 | 111.4 | 138.0 | 55.5 | 22.3 | 58.7 | 60.2 | 0.0 | |
| Total Cash & ST Investments | 184.5 | 218.0 | 251.7 | 290.1 | 271.1 | 297.7 | 162.8 | 192.0 | 155.2 | 208.8 | |
| Accounts Receivable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.9 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -33.4 | |
| Other Current Assets | 3.7 | 3.1 | 3.1 | 2.6 | 3.0 | 1.9 | 1.9 | 2.2 | 2.1 | 1.5 | |
| Total Current Assets | 188.2 | 221.1 | 254.8 | 292.7 | 274.1 | 299.5 | 164.7 | 194.2 | 155.2 | 208.8 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 68.6 | 71.6 | 71.2 | 69.2 | 17.3 | 12.5 | 6.4 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 1.7 | 6.8 | 6.7 | 9.9 | 5.2 | 0.8 | 0.6 | |
| Total Long-Term Assets | 75.3 | 78.4 | 77.9 | 79.1 | 22.5 | 13.3 | 7.0 | |
| Total Assets | 374.9 | 371.1 | 272.1 | 199.1 | 188.1 | 49.7 | 49.4 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 68.7 | 70.6 | 71.1 | 71.6 | 67.1 | 68.6 | 69.4 | 71.2 | 67.1 | 68.0 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 | 5.0 | 5.0 | |
| Other Long-Term Assets | 0.3 | 6.8 | 6.8 | 6.8 | 6.8 | 6.8 | 6.7 | 1.6 | 64.0 | 35.0 | |
| Total Long-Term Assets | 74.1 | 77.4 | 77.9 | 78.4 | 73.9 | 75.3 | 76.1 | 77.9 | 136.2 | 108.1 | |
| Total Assets | 262.2 | 298.6 | 332.7 | 371.1 | 348.0 | 374.9 | 240.8 | 272.1 | 291.4 | 316.9 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 3.1 | 4.3 | 2.4 | 2.9 | 1.8 | 2.9 | 1.0 | |
| Short-Term Debt | 14.0 | 4.6 | 9.8 | 3.7 | 1.7 | 1.4 | 0.4 | |
| Other Current Liabilities | 10.8 | 15.4 | 7.5 | 6.8 | 6.5 | 2.5 | 0.0 | |
| Current Liabilities | 38.6 | 36.0 | 29.8 | 17.3 | 21.3 | 17.4 | 2.4 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 6.4 | 4.5 | 5.0 | 4.3 | 3.6 | 3.1 | 2.1 | 2.4 | 3.2 | 3.4 | |
| Short-Term Debt | 6.9 | 6.3 | 5.0 | 4.6 | 3.9 | 17.6 | 10.1 | 9.8 | 9.9 | 8.4 | |
| Other Current Liabilities | 10.8 | 12.8 | 9.6 | 15.4 | 11.2 | 7.2 | 19.2 | 7.5 | 4.9 | 4.1 | |
| Current Liabilities | 29.2 | 31.3 | 29.8 | 36.0 | 28.7 | 38.6 | 31.5 | 29.8 | 33.2 | 35.1 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 20.1 | 92.8 | 85.8 | 82.3 | 4.4 | 6.0 | 4.4 | |
| Capital Leases | 57.0 | 65.3 | 62.4 | 56.7 | 6.0 | 7.4 | 4.9 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 59.7 | 0.0 | |
| Total Liabilities | 119.7 | 130.1 | 121.3 | 99.7 | 27.3 | 92.2 | 66.5 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 88.7 | 90.4 | 92.1 | 92.8 | 86.5 | 77.1 | 81.6 | 85.8 | 81.5 | 83.5 | |
| Capital Leases | 0.0 | 64.4 | 64.9 | 65.3 | 59.7 | 60.6 | 61.5 | 59.1 | 57.0 | 58.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 118.2 | 121.8 | 122.5 | 130.1 | 118.9 | 119.7 | 117.9 | 121.3 | 122.4 | 126.3 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -309.4 | -375.1 | -247.6 | -158.4 | -92.2 | -43.5 | -17.4 | |
| Comprehensive Income | 0.0 | 0.1 | 0.0 | 0.0 | -188.1 | 0.0 | 0.0 | |
| Total Common Equity | 255.2 | 241.0 | 150.9 | 99.4 | 160.8 | -42.5 | -17.1 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -481.9 | -446.2 | -409.2 | -375.1 | -339.3 | -309.4 | -277.7 | -247.6 | -228.0 | -205.0 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Common Equity | 144.0 | 176.7 | 210.2 | 241.0 | 229.1 | 255.2 | 123.0 | 150.9 | 169.0 | 190.6 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Debt | 91.1 | 97.4 | 92.4 | 86.0 | 6.0 | 7.4 | 4.9 | |
| Book Value | 255.2 | 241.0 | 150.9 | 99.4 | 160.8 | -42.5 | -17.1 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 144.0 | 176.7 | 210.2 | 241.0 | 229.1 | 255.2 | 123.0 | 150.9 | 169.0 | 190.6 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -104.4 | -129.8 | -127.5 | -89.2 | -66.2 | -48.6 | -26.1 | -13.7 | |
| Depreciation & Amortization | 4.9 | 2.9 | 4.1 | 5.4 | 5.1 | 3.3 | 1.2 | 0.5 | |
| Stock-Based Compensation | 7.2 | 11.7 | 9.5 | 5.2 | 4.6 | 2.5 | 0.5 | 0.2 | |
| Change Working Capital | 22.3 | -18.2 | 5.1 | 17.6 | -10.2 | -5.9 | 21.4 | 0.3 | |
| Change In Accounts Receivable | 31.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | -0.9 | -3.0 | 2.0 | -0.1 | 0.5 | 0.0 | 1.1 | 0.2 | |
| Change In Inventories | -31.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 12.8 | -1.9 | -2.0 | -0.3 | 0.3 | 0.0 | 0.0 | 0.1 | |
| Cash from Operations | -71.2 | 0.0 | 0.0 | -61.4 | -66.5 | -48.7 | -3.0 | -12.5 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -23.0 | -35.7 | -37.0 | -34.1 | -35.8 | -29.9 | -31.7 | -30.1 | -19.6 | -23.0 | |
| Depreciation & Amortization | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 | 1.0 | 1.1 | 1.3 | 1.3 | 1.3 | |
| Stock-Based Compensation | 2.0 | 3.0 | 3.3 | 3.4 | 2.7 | 2.5 | 2.3 | 2.0 | 1.5 | 1.3 | |
| Change Working Capital | -11.8 | -0.4 | 0.4 | -6.4 | 5.3 | -0.3 | 2.2 | -2.1 | -6.2 | 28.4 | |
| Change In Accounts Receivable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.9 | |
| Change In Accounts Payable | -5.1 | 1.9 | -0.4 | 0.6 | 1.0 | 1.0 | 0.4 | -0.4 | -0.6 | -0.3 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -31.9 | |
| Other Non-cash Items | 0.1 | -0.2 | -0.7 | -1.2 | -0.3 | -1.3 | -0.2 | -0.3 | 4.0 | 0.2 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -23.8 | 8.0 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -3.5 | -4.4 | -3.8 | -3.1 | -4.2 | -9.9 | -4.2 | -1.2 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -134.7 | -87.5 | -241.4 | -77.6 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 81.1 | 201.3 | 192.7 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | -20.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | -57.1 | 0.0 | 0.0 | -60.8 | -4.2 | -9.9 | -4.2 | -1.2 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.2 | -1.4 | -1.3 | -1.5 | -0.9 | -1.4 | -0.9 | -0.7 | -0.5 | -1.4 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | -26.5 | -60.9 | -47.3 | -137.0 | -48.4 | -8.8 | -17.6 | -60.0 | |
| Sales of Investment | 15.0 | 34.0 | 76.3 | 76.0 | 75.5 | 56.0 | 15.5 | 45.6 | 20.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | -60.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 | -61.4 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 3.3 | 97.4 | 4.9 | 6.4 | 80.3 | -1.4 | 2.5 | 4.9 | |
| Issuance of Common Stock | 161.6 | 0.0 | 0.0 | 42.4 | 0.2 | 89.6 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.2 | 0.0 | 0.0 | 93.0 | 29.5 | 100.0 | 0.0 | 0.0 | |
| Cash from Financing | 161.6 | 0.0 | 0.0 | 135.4 | 29.4 | 189.7 | 0.3 | 34.8 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 95.6 | -1.1 | -0.3 | -0.3 | 7.0 | -4.3 | 2.9 | -0.7 | 5.5 | -0.8 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 33.3 | -26.3 | 45.3 | 13.3 | -41.4 | 131.1 | -7.0 | 21.0 | |
| Closing Cash Balance | 242.2 | 157.4 | 183.7 | 138.4 | 125.1 | 166.4 | 35.4 | 42.4 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -17.1 | 0.1 | 15.3 | -24.6 | 45.6 | -109.0 | 101.6 | 7.2 | -21.8 | -53.6 | |
| Closing Cash Balance | 157.4 | 169.5 | 174.4 | 159.1 | 183.7 | 138.1 | 247.2 | 145.5 | 133.4 | 160.2 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -74.7 | -139.7 | -114.6 | -64.5 | -70.7 | -58.6 | -7.3 | -13.8 | |
| Real Free Cash Flow | -81.8 | -151.4 | -124.2 | -69.7 | -75.3 | -61.1 | -7.8 | -14.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -32.2 | -33.9 | -34.5 | -39.1 | -28.3 | -29.3 | -27.1 | -30.0 | -24.2 | 6.6 | |
| Real Free Cash Flow | -34.2 | -36.9 | -37.8 | -42.5 | -31.0 | -31.8 | -29.4 | -32.0 | -25.7 | 5.3 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -1 | -2.7 | -1.4 |
| P/S | 13.1 | 26.2 | 9.4 |
| P/B | 0.9 | 1.1 | 5.2 |
| P/FCF | -0.9 | -2.8 | -1.5 |
| Market cap | $0.1 | $4.6 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 36.5 % | 20.4 % | 0 % |
| Debt to Income | -73.7 % | -143.3 % | 0 % |
| Debt to Free cash flow | -63.1 % | -311.2 % | 0 % |
| Interest expense percentage | -2 % | -1.2 % | 44.7 % |
| Current ratio | 6.4 | 5.9 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -90.1 % | -33.8 % | 0 % |
| ROA | -49.5 % | -30.1 % | 0 % |
| CapEx to Revenue | 60.8 % | 116 % | 0 % |
| RaD to Revenue | 0 % | 899.3 % | 0 % |
| ROEM | 53,221.6 | 48878.3 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 90.9 % | 80.5 % | 68.7 % |
| Operating margin | -1765 % | -1158.1 % | 35.5 % |
| Net margin | -1693 % | -1128.7 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 129.8 mil | 57.1 mil |
| Employee count | 0.2 tis | 0.1 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
